Tags : P-IIIb

Novartis Reports Results of Enerzair Breezhaler (QVM149) in P-IIIb ARGON

Shots: The P-IIIb ARGON study involves assessing of IND/GLY/MF (150/50/80 μg , 150/50/160 μg, qd) with Sal/Flu (50/500μg, bid) delivered via Diskus + tiotropium (5 μg), delivered via Respimat in 1251 patients in a ratio (1:1:1) aged ≥18yrs. with uncontrolled asthma The study resulted in meeting its 1EPs demonstrating non-inferiority in change AQLQ. 2EPS include […]Read More

Roche Reports Updated Results of Hemlibra (emicizumab) in P-III HAVEN

Shots: The P-III HAVEN (1,2,3, & 4) studies involve assessing of Hemlibra in patients with hemophilia A with/out factor VIII inhibitors resulted in zero treat bleeds @83wks., 87% with no treated joint bleeds, 92% with no spontaneous bleeds @25wks., improvement in QoL The P-IIIb STASEY study reinforces safety profile of Hemlibra in 88 patients with […]Read More

Teva Reports Results of Fremanezumab in P-IIIb FOCUS Study for

Shots: The P-IIIb FOCUS study involves assessing of fremanezumab (quarterly & monthly) vs PBO in patients in a ratio (1:1:1) with episodic/chronic migraine (EM/CM) prior treated with two to four classes of preventive therapy The P-IIIb FOCUS study results: @3mos. reduction in monthly migraine days; reduction in migraine-related symptoms; improvement in disability & QOL; improvements […]Read More